Manufacturer:
Amneal Pharmaceuticals
Route of Administration:
Subcutaneous
Site of Care:
Outpatient
Website:
phone:
866-4AMNEAL (866-426-6325)
Approved Indication:
- to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
- to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
- to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
- to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
- to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
Conditions:
- Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
- Hematopoietic Stem Cell Transplantation
- Cyclic/Congenital/Idiopathic Neutropenia
- Hematopoietic Syndrome of Acute Radiation Syndrome
Therapeutic Area:
- Oncology